The novel KRAS mutant E31D, which also harbored a conserved amino acid substitution, was predicted to be benign in all in silico prediction platforms used, but showed highly oncogenic properties in all cancer hallmarks tested [57]. The gene discussed is KRAS; the disease is cancer.